Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Myriad Genetics, Inc (NASDAQ: MYGN) was $12.91 for the day, up 2.95% from the previous closing price of $12.54. In other words, the price has increased by $2.95 from its previous closing price. On the day, 1.7 million shares were traded. MYGN stock price reached its highest trading level at $13.1014 during the session, while it also had its lowest trading level at $12.38.
Ratios:
Our analysis of MYGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on December 10, 2024, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 09, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $30 to $21.
On September 19, 2024, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $32.Morgan Stanley initiated its Equal-Weight rating on September 19, 2024, with a $32 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1175264384 and an Enterprise Value of 1218464768. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.43 while its Price-to-Book (P/B) ratio in mrq is 1.61. Its current Enterprise Value per Revenue stands at 1.479 whereas that against EBITDA is -35.943.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.89, which has changed by -0.41043723 over the last 52 weeks, in comparison to a change of 0.21794415 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $12.04. The 50-Day Moving Average of the stock is -9.35%, while the 200-Day Moving Average is calculated to be -40.56%.
Shares Statistics:
MYGN traded an average of 1.07M shares per day over the past three months and 1165050 shares per day over the past ten days. A total of 91.00M shares are outstanding, with a floating share count of 87.62M. Insiders hold about 3.75% of the company’s shares, while institutions hold 100.57% stake in the company. Shares short for MYGN as of 1736899200 were 4811940 with a Short Ratio of 4.48, compared to 1734048000 on 3349808. Therefore, it implies a Short% of Shares Outstanding of 4811940 and a Short% of Float of 7.39.
